Russia now has its first domestic epilepsy therapy, a drug called Lacosamide PSK


PSK Pharma has launched onto the market Lacosamide PSK (INN lacosamide), Russia’s first domestic antiepileptic drug. This was reported in the company’s press service.

“The first foreign Lacosamide appeared on the Russian market in 2009, and until 2022 doctors had no domestically-produced alternatives. This month, PSK Pharma received a registration certificate for Lacosamide PSK in the form of film-coated tablets in four different dosages: 50, 100, 150, and 200 mg. The domestic drug will be available to patients in the near future, at a cost lower than that of the foreign-made drug,” the report says.

Epilepsy is a chronic disease in which regular medicinal therapy can achieve sustained remission. One of the possible options for patients over the age of 16 is therapy with drugs containing  lacosamide (active substance).  Such treatment helps to reduce the increased excitability of neuronal membranes, and also controls the processes of neuronal differentiation and axonal growth, the company stressed.

“We are pleased to announce the launch of the first Russian drug, Lacosamide PSK, with lacosamide as the active ingredient. It is produced at our facilities in Dubna, where all stages of its manufacturing take place, as well as quality control. This is the first drug for the treatment of epilepsy in our portfolio, which we develop in a systematic manner based on the needs of Russian healthcare. We are confident that it is going to be in demand and are trying to make it as available and affordable as possible. Our priority is to provide patients with highly effective domestic drugs for the treatment of socially significant diseases,” said Evgenia Shapiro, PSK Pharma’s CEO.

Lacosamide is included in the vital and essential drugs list (VED).